A Study Of Neoadjuvant-treated Stage III Melanoma

Overview

About this study

The purpose of this study is to identify biomarker(s) and/or algorithms incorporating baseline patient clinical, tumor, blood and microbiome data to guide selection of the optimal neoadjuvant regimen for patients with clinical stage III melanoma. Specifically, identify a robust pre-treatment marker that predicts a high rate of major pathologic response to the least toxic neoadjuvant immunotherapy regimen, e.g. anti-PD-1 monotherapy or similar low toxicity regimen.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:  

  • Patients with Stage III melanoma planned for neoadjuvant systemic therapy.

 

Exclusion Criteria: 

  • Patients unable to provide written informed consent. Patients with unresectable or Stage IV melanoma.

 

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/15/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Tina Hieken

Contact us for the latest status

Contact information:

Tina Hieken

(507) 284-2166

hieken.tina@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20597156

Mayo Clinic Footer